[go: up one dir, main page]

SG11202006387QA - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
SG11202006387QA
SG11202006387QA SG11202006387QA SG11202006387QA SG11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA SG 11202006387Q A SG11202006387Q A SG 11202006387QA
Authority
SG
Singapore
Prior art keywords
protein conjugate
conjugate composition
pneumococcal polysaccharide
multivalent pneumococcal
multivalent
Prior art date
Application number
SG11202006387QA
Inventor
Kyungjun An
Dongsoo Ham
Hun Kim
Sunghyun Kim
Jinhwan Shin
Robert Hopfer
Richard Kensinger
Moe Kyaw
Philippe Talaga
Original Assignee
Sanofi Pasteur Inc
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc, Sk Bioscience Co Ltd filed Critical Sanofi Pasteur Inc
Publication of SG11202006387QA publication Critical patent/SG11202006387QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG11202006387QA 2018-02-05 2019-02-04 Multivalent pneumococcal polysaccharide-protein conjugate composition SG11202006387QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626482P 2018-02-05 2018-02-05
KR20180045246 2018-04-18
PCT/US2019/016506 WO2019152921A1 (en) 2018-02-05 2019-02-04 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (1)

Publication Number Publication Date
SG11202006387QA true SG11202006387QA (en) 2020-07-29

Family

ID=67478950

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006387QA SG11202006387QA (en) 2018-02-05 2019-02-04 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (14)

Country Link
US (2) US11147864B2 (en)
EP (1) EP3749358A4 (en)
JP (1) JP7288451B2 (en)
KR (1) KR102812816B1 (en)
CN (1) CN111757754B (en)
AU (1) AU2019215212B2 (en)
BR (1) BR112020014978A2 (en)
IL (1) IL276229B2 (en)
MX (1) MX2020007939A (en)
PH (1) PH12020551147A1 (en)
SA (1) SA520412580B1 (en)
SG (1) SG11202006387QA (en)
TW (1) TWI815860B (en)
WO (1) WO2019152921A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2022001241A (en) 2019-07-31 2022-04-20 Sanofi Pasteur Inc COMPOSITIONS OF MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS FOR USE THEREOF.
WO2021229604A1 (en) * 2020-05-14 2021-11-18 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
KR20250107930A (en) * 2022-11-22 2025-07-14 화이자 인코포레이티드 Immunogenic composition comprising conjugated membrane saccharide antigen and use thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) * 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
ATE245446T1 (en) 1992-02-11 2003-08-15 Jackson H M Found Military Med DUAL CARRIER FOR IMMUNOGENIC CONSTRUCTS
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
PT616034E (en) 1993-03-05 2005-02-28 Wyeth Corp PLASMIDEO FOR THE PRODUCTION OF PROTEIN CRM AND DIPHTHERIA TOXIN
JP3828145B2 (en) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
JP3468773B2 (en) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション Immunomodulatory oligonucleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996025425A1 (en) 1995-02-16 1996-08-22 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
CA2153733A1 (en) 1995-07-12 1997-01-13 Andrew J. Malcolm Immunogenic oligosaccharide compositions
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
CA2153730A1 (en) 1995-07-12 1997-01-13 Andrew J. Malcolm Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
KR19990007777A (en) 1995-06-07 1999-01-25 듀크두플레시스 Immune and immunostimulatory oligosaccharide compositions and methods of making and using them
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP2001513776A (en) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
WO1999051259A2 (en) 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DE122009000054I1 (en) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa VACCINE AGAINST BACTERIAL ANTIGENE
FR2806304B1 (en) 2000-03-17 2002-05-10 Aventis Pasteur POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA
DZ3399A1 (en) 2000-06-29 2002-01-03 Smithkline Beecham Biolog VERSATILE VACCINE COMPOSITION
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US7118756B2 (en) 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
AU2007200116A1 (en) 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
CN1636062A (en) 2001-04-16 2005-07-06 惠氏控股公司 Streptococcus neopneumoniae open reading frame encoding polypeptide antigen and its application
TWI346555B (en) 2002-04-01 2011-08-11 Glaxosmithkline Biolog Sa Vaccine composition
TWI341210B (en) 2002-04-01 2011-05-01 Glaxosmithkline Biolog Sa Vaccine kit
KR101052996B1 (en) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. Purification Process for Bacterial Cell Lysis
US7320874B2 (en) 2003-07-08 2008-01-22 Aventis Pasteur Sa Assaying the teichoic acids of gram+ bacteria
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
CN104815327A (en) * 2005-04-08 2015-08-05 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE050049T2 (en) 2005-04-08 2020-11-30 Wyeth Llc Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT1973564T (en) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
US8808707B1 (en) * 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008045852A2 (en) 2006-10-10 2008-04-17 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
UA99278C2 (en) 2007-03-23 2012-08-10 УАЙЕТ ЭлЭлСи Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
RU2536248C2 (en) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Pneumococcal vaccine and using it
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (en) 2010-03-05 2012-09-26 成都安特金生物技术有限公司 Novel pneumococcal conjugate vaccine and preparation method thereof
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN102068690A (en) 2010-12-31 2011-05-25 北京民海生物科技有限公司 Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof
KR102057217B1 (en) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
PT2885007T (en) 2012-08-16 2018-12-10 Pfizer Glycoconjugation processes and compositions
CN103656631B (en) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 multivalent pneumococcal capsular polysaccharide-protein conjugate composition and preparation method thereof
CN103656632B (en) 2012-09-24 2016-01-13 北京科兴中维生物技术有限公司 Multivalent pneumococcal capsular polysaccharide composition, its preparation method and application
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
ITMI20130142A1 (en) 2013-01-31 2014-08-01 Biosynth Srl GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (en) 2014-01-21 2023-12-26 Pfizer Inc PROCESS FOR PREPARING CONJUGATES COMPRISING CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE
HRP20211288T1 (en) 2014-01-21 2021-11-26 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CN104225589B (en) 2014-07-25 2018-02-09 武汉博沃生物科技有限公司 A kind of conjugated vaccine and preparation method thereof
FI3244917T3 (en) 2015-01-15 2023-05-25 Pfizer Immunogenic compositions for use in pneumococcal vaccines
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN106140046B (en) 2016-07-06 2019-02-22 江南大学 Array Type Induced Electric Field Fluid Reactor System and Its Application
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017336806B2 (en) * 2016-09-30 2024-06-27 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2022001241A (en) 2019-07-31 2022-04-20 Sanofi Pasteur Inc COMPOSITIONS OF MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS FOR USE THEREOF.

Also Published As

Publication number Publication date
CN111757754B (en) 2024-07-05
CA3087572A1 (en) 2019-08-08
TWI815860B (en) 2023-09-21
WO2019152921A1 (en) 2019-08-08
IL276229B2 (en) 2024-01-01
IL276229B1 (en) 2023-09-01
TW201945028A (en) 2019-12-01
AU2019215212A1 (en) 2020-07-23
KR20200121822A (en) 2020-10-26
KR102812816B1 (en) 2025-05-27
US11147864B2 (en) 2021-10-19
IL276229A (en) 2020-09-30
JP2021512870A (en) 2021-05-20
US20220031828A1 (en) 2022-02-03
JP7288451B2 (en) 2023-06-07
US20200360502A1 (en) 2020-11-19
EP3749358A4 (en) 2022-04-20
MX2020007939A (en) 2020-09-03
CN111757754A (en) 2020-10-09
EP3749358A1 (en) 2020-12-16
AU2019215212B2 (en) 2025-05-15
PH12020551147A1 (en) 2021-05-31
SA520412580B1 (en) 2024-02-21
BR112020014978A2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
ZA202202600B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL276229B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
ZA201901346B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL265623A (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
ZA201901345B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
IL297740B2 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
SG11202102007UA (en) Multivalent pneumococcal vaccines
IL284349A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
LT3585803T (en) Pneumococcal conjugate vaccine formulations
EP3576784A4 (en) Methods for making polysaccharide-protein conjugates
IL268168A (en) Immunogenic compositions for use in pneumococcal vaccines
ZA201708713B (en) Multivalent pneumococcal conjugate vaccine
ZA201708325B (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
GB201802339D0 (en) Immunogenic composition
ZA201901969B (en) A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof
SG11201911757WA (en) Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereof
IL279855B2 (en) Improvements in immunogenic conjugates
ZA202103644B (en) Multivalent glycoconjugates immunogenic compositions
HK40033343A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
HK40033342A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
GB201803692D0 (en) Immunogenic composition
HK40075160A (en) Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
HK40046980A (en) Multivalent pneumococcal vaccines
GB201820010D0 (en) Immunogenic composition
AU2013360597B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition